文献速递骨软组织肉瘤与黑色素瘤

联合临床病理因素与基因表达谱的模型(CP-GEP)识别复发高危的I/II期黑色素瘤患者

Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP).
PubMed 文献 · Eur J Cancer · 2022-12-30

研究纳入543例2000至2017年间在Tuebingen大学诊断的I/II期原发性皮肤黑色素瘤患者,所有患者均接受前哨淋巴结活检(SLNB),另对80例未行SLNB的患者单独分析。CP-GEP将424例I/IIA期患者(占队列78%)按复发风险分层,高风险组(195例)与低风险组(229例)的5年无复发生存率分别为77.8%和93%,风险比HR 3.53(P<0.001);未行SLNB的患者中,CP-GEP捕获了7例复发中的6例。结论认为CP-GEP可用于识别复发高危的I/IIA期患者,这些患者可能从辅助治疗中获益。

要点

  • CP-GEP将78%(424例)的I/IIA期患者按复发风险分层,高风险组195例与低风险组229例的5年RFS分别为77.8%和93%,HR 3.53(P<0.001)。
  • 未行SLNB的80例患者中,CP-GEP捕获了7例复发中的6例。
  • CP-GEP可识别被AJCC第8版视为低风险的I/IIA期患者中的复发高危者,这些患者可能从辅助治疗中获益。

核心结论

  • CP-GEP可用于识别原发性皮肤黑色素瘤复发高危患者,尤其是被AJCC第8版视为低风险的I/IIA期患者,这些患者可能从辅助治疗中获益。
  • 未来当SLNB可能不再重要时,CP-GEP或可作为风险分层工具。

研究设计与样本

  • 研究分析了2000至2017年间在Tuebingen大学诊断的543例I/II期原发性皮肤黑色素瘤患者,所有患者均接受前哨淋巴结活检(SLNB)。
  • 另对80例未行SLNB的患者进行了单独分析。

主要发现

  • CP-GEP将424例I/IIA期患者(占队列78%)按复发风险分层,高风险组195例与低风险组229例的5年无复发生存率(RFS)分别为77.8%和93%,风险比HR 3.53(P<0.001)。
  • 在未行SLNB的患者中,CP-GEP捕获了7例复发中的6例。

临床怎么用

  • 作者认为CP-GEP可用于识别复发高危的I/IIA期皮肤黑色素瘤患者,这些患者可能从辅助治疗中获益。
  • 作者提出未来当SLNB可能不再重要时,CP-GEP或可作为风险分层工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with cutaneous melanoma stage I/IIA disease are currently not eligible for adjuvant therapy, despite their risk for relapses and death. This study validates the ability of a model combining clinicopathologic factors with gene expression profiling (CP-GEP) to identify patients at high risk for disease recurrence in stage I/II and subgroup stage I/IIA. PATIENTS AND METHODS: 543 patients with stage I/II primary cutaneous melanoma from the University of Tuebingen diagnosed between 2000 and 2017 were analysed. All patients received sentinel lymph node biopsy (SLNB). Analysis was conducted for a separate group of 80 patients who did not undergo SLNB. RESULTS: CP-GEP stratified 424 stage I/IIA patients (78% of the cohort) according to their risk for recurrence, with five-year relapse-free survival (RFS) rates of 77.8% and 93% for CP-GEP high risk (195 patients) and low risk (229 patients), respectively, and hazard ratio of 3.53 (p-value <0.001). In patients who did not receive SLNB biopsy, CP-GEP captured 6 out of 7 relapses. CONCLUSION: CP-GEP can be used to identify primary cutaneous melanoma patients with a high risk for disease recurrence - especially for stage I/IIA, who are considered low risk by AJCC 8th. These patients may benefit from adjuvant therapy. Also, in the future, when SLNB may become irrelevant, CP-GEP may serve as a risk stratification tool.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Amaral T, Sinnberg T, Chatziioannou E, et al. Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP). Eur J Cancer. 2022. PMID: 36739215. doi:10.1016/j.ejca.2022.12.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。